Alterity Therapeutics (ATH) Canaccord Genuity's 46th Annual Growth Conference summary

Key clinical and scientific insights

• ATH434 demonstrated up to 50% slowing of disease progression in phase II for multiple system atrophy (MSA), using an FDA-recognized endpoint.

• The drug targets iron accumulation in the brain, a key driver of pathology in MSA and Parkinson's disease, by redistributing excess iron and reducing neuronal damage.

• Phase II results showed significant improvements in mobility, swallowing, and orthostatic hypotension, with the 50 mg dose selected for phase III due to optimal efficacy and safety.

• Neuroimaging and biomarker studies confirmed reduced iron accumulation and blunted brain atrophy in treated patients, supporting the drug's mechanism.

• No severe or serious adverse events attributed to the drug were observed, and the safety profile was comparable to placebo.

Regulatory and development progress

• Positive end-of-phase II meeting with the FDA resulted in agreement on endpoints, patient population, and dosing for phase III.

• Phase III will enroll approximately 200 MSA patients, using the 50 mg dose, with primary and secondary endpoints aligned with prior studies.

• The drug holds orphan status in the US and Europe and has Fast Track designation in the US.

• Patent portfolio expansion is underway, with anticipated near-term IP developments to broaden commercial opportunities.

Commercial outlook and market opportunity

• MSA affects 20,000–50,000 patients in the US, with no approved therapies, representing a significant unmet need.

• Commercial assessment with US neurologists showed over 70% strong intent to prescribe based on the target product profile.

• Peak sales are estimated at $2.4 billion under conservative assumptions, with future catalysts expected in 2026.